GammaDelta Therapeutics initiates first-in-human phase 1 trial of GDX012 for the treatment of acute myeloid leukemia
GammaDelta Therapeutics Ltd. (GDT), a biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for
Read more